Stockreport

Alexion Receives Positive CHMP Opinion for SOLIRIS® (eculizumab) for the Treatment of NMOSD

Alexion Pharmaceuticals, Inc  (ALXN) 
Last alexion pharmaceuticals, inc earnings: 1/30 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.alexion.com/investor-relations
PDF - At 48 weeks, 98% of adult patients who are anti-aquaporin-4 (AQP4) antibody positive and were treated with SOLIRIS were relapse free compared to 63% receiving placebo [Read more]